bioMerieux (OTCMKTS:BMXMF) Stock Rated “Reduce” by Sell-Side Brokerages

bioMerieux (OTCMKTS:BMXMF) has received an average recommendation of “Reduce” from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and five have issued a hold rating on the company.

A number of brokerages recently commented on BMXMF. Morgan Stanley reaffirmed an “underweight” rating on shares of bioMerieux in a research note on Friday, September 11th. Zacks Research raised shares of bioMerieux from a “strong sell” rating to a “hold” rating in a research report on Monday, September 28th.

bioMerieux Price Performance

BMXMF opened at $99.63 on Monday. bioMerieux has a 52-week low of $77.00 and a 52-week high of $132.05. The stock’s 50 day moving average price is $88.01 and its 200-day moving average price is $85.98.

bioMerieux Company Profile

bioMérieux is a France-based company specializing in in vitro diagnostics. It develops and manufactures diagnostic systems, reagents, software and services used to detect disease, identify infectious organisms and support treatment decisions. Its offerings serve hospitals, clinical laboratories and other healthcare providers, with a particular focus on infectious diseases, antimicrobial resistance and syndromic testing.

The company also provides industrial microbiology solutions for applications such as food safety, pharmaceutical manufacturing and quality control.